Clinical Usefulness of Serum CYFRA 21-1 in Patients with Colorectal Cancer

被引：16

作者：

Lee J.H. ^{[1
]}

机构：

[1] Department of Nuclear Medicine, Dankook University Medical College, Cheonan, 330-715, Dongnam-ku, Anseo-dong

来源：

Nuclear Medicine and Molecular Imaging | 2013年 / 47卷 / 3期

关键词：

CEA and CA 19-9; Colorectal cancer; CYFRA; 21-1;

D O I：

10.1007/s13139-013-0218-4

中图分类号：

学科分类号：

摘要：

Purpose: Among diverse tumor markers, pretreatment evaluation and follow-up detection of recurrence in colorectal cancer are generally evaluated by serum carcinoembryonic antigen (CEA) levels. However, there have been some reports about the low accuracy and high false-positive results of CEA in colorectal cancer. We investigated the clinical utilities of CYFRA 21-1 by comparing CEA and cancer antigen 19-9 (CA 19-9) in pretreatment and recurrent colorectal cancer. Methods: Using a solid-phase immunoradiometric assay, serum levels of CYFRA 21-1, CEA and CA 19-9 were analyzed in 132 patients with primary colorectal cancer, 124 healthy controls, 104 patients with benign colorectal disease and 19 patients with recurrent colorectal cancer. We determined three different cutoff values to evaluate the sensitivity of diagnostic performance in pretreatment and recurrent colorectal cancer. Results: CYFRA 21-1 (≥ 1.13 ng/ml) had a sensitivity of 47 %, compared with 37 % for CEA (≥ 3.05 ng/ml) and 32.6 % for CA 19-9 (≥ 23.1 ng/ml) in the initial staging of primary colorectal cancer. Using different cutoff values, CYFRA 21-1 showed higher sensitivity for pretreatment colorectal cancer than CEA and CA 19-9 in adenocarcinoma and adenosquamous carcinoma of this study. A mildly significant correlative relationship was noted between Dukes' stages and three tumor markers (p < 0.01). The areas under the receiver operating characteristic curves of CYFRA 21-1, CEA and CA 19-9 were 0.81 ± 0.03, 0.74 ± 0.03 and 0.62 ± 0.04, respectively, for discriminating colorectal cancer patients from patients with benign colorectal disease. In addition, CYFRA 21-1 was determined as the most sensitive tumor marker for evaluating recurrent colorectal cancer for all cutoff values. Conclusion: This study showed that CYFRA 21-1 could be a useful and dependable tumor marker for pretreatment and recurrent colorectal cancer. Further prospective studies on its usefulness with respect to the prognosis and utility of combined tumor markers are needed. © 2013 Korean Society of Nuclear Medicine.

引用

页码：181 / 187

页数：6

共 36 条

[11]

van der Schouw Y.T., Verbeek A.L., Wobbes T., Segers M.F., Thomas C.M., Comparison of four serum tumour markers in the diagnosis of colorectal carcinoma, Br J Cancer, 66, pp. 148-154, (1992)

[12]

Chapman M.H., Sandanayake N.S., Andreola F., Dhar D.K., Webster G.J., Dooley J.S., Et al., Circulating CYFRA 21-1 is a specific diagnostic and prognostic biomarker in biliary tract cancer, J Clin Exp Hepatol, 1, pp. 6-12, (2011)

[13]

Verwaal V., Zoetmulder F., Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin, Eur J Surg Oncol, 30, pp. 280-285, (2004)

[14]

Yang S.H., Lin J.K., Lai C.R., Chen C.C., Li A., Liang W.Y., Et al., Risk factors for peritoneal dissemination of colorectal cancer, J Surg Oncol, 87, pp. 167-173, (2004)

[15]

Zheng C.X., Zhan W.H., Zhao J.Z., Zheng D., Wang D.P., He Y.L., Et al., The prognostic value of preoperative serum levels of CEA, CA19-9 and CA72-4 in patients with colorectal cancer, World J Gastroenterol, 7, pp. 431-434, (2001)

[16]

Kantoush A.A., Ahmed M.M., Bushra S.S., Evaluation of cyfra 21-1 as a diagnostic tool in lung cancer, J Appl Sci Res, 5, pp. 1195-1201, (2009)

[17]

Lumachi F., Marino F., Orlando R., Chiara G.B., Basso S.M.M., Simultaneous multianalyte immunoassay measurement of five serum tumor markers in the detection of colorectal cancer, Anticancer Res, 32, pp. 985-988, (2012)

[18]

Giovanella L., Ceriani L., Giardina G., Bardelli D., Tanzi F., Garancini S., Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA), Clin Chem Lab Med, 40, pp. 298-303, (2002)

[19]

Brechot J., Chevret S., Nataf J., Le Gall C., Fretault J., Rochemaure J., Et al., Diagnostic and prognostic value of cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients, Eur J Cancer, 33, pp. 385-391, (1997)

[20]

Molina R., Filella X., Auge J., Fuentes R., Bover I., Rifa J., Et al., Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis, Tumor Biol, 24, pp. 209-218, (2003)

← 1 2 3 4 →